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Intellectual disability (ID) is one of the many features manifested in various genetic
syndromes leading to deficits in cognitive function among affected individuals. ID is a
feature affected by polygenes and multiple environmental factors. It leads to a broad
spectrum of affected clinical and behavioral characteristics among patients. Until now,
the causative mechanism of ID is unknown and the progression of the condition is
poorly understood. Advancement in technology and research had identified various genetic
abnormalities and defects as the potential cause of ID. However, the link between these
abnormalities with ID is remained inconclusive and the roles of many newly discovered
genetic components such as non-coding RNAs have not been thoroughly investigated.
In this review, we aim to consolidate and assimilate the latest development and findings
on a class of small non-coding RNAs known as microRNAs (miRNAs) involvement in ID
development and progression with special focus on Down syndrome (DS) and X-linked ID
(XLID) [including Fragile X syndrome (FXS)].
Keywords: Down syndrome, brain development, cognitive function, Fragile X syndrome, X-linked genetic disease,
non-coding RNA, neuronal development, mental retardation
INTRODUCTION
Intellectual disability (ID), also known as mental retardation,
is the most common developmental disability and affects about
1–3% of the world population. It is a condition defined as having
a significantly impaired cognitive ability and adaptive behaviors
before the age of 18 (Daily et al., 2000). In clinical practice, diag-
nosis of ID in a patient is based on the intelligence quotient
(IQ) below 70 at the age of 5 or older and deficits in two or
more adaptive behaviors, such as communication, self-care, social
skills, community access skills, self-direction, health, and safety
(Kaufmann et al., 2007; Van Bokhoven, 2011). Conventionally,
ID is divided into two distinctive groups; syndromic ID and non-
syndromic ID. In syndromic ID, patients are presented with addi-
tional clinical features such as physical deformities or metabolic
defects whereas intellectual impairment is the sole clinical features
for non-syndromic ID (Kaufman et al., 2010; Van Bokhoven,
2011). However, there are considerable challenges in distinguish-
ing both groups as some clinical features are very subtle and
difficult to be diagnosed. Therefore, multiple comparisons have
to be made between patients with common etiology to identify
the genetic defects associated with the clinical features presented.
In addition to the classification based on clinical features, ID
can be categorized according to the level of severity based on IQ of
the patient. Patients with IQ below 20 is categorized as profound
ID, IQ of 20–34 as severe ID, IQ of 35–49 as moderate ID, and
IQ of 50–70 as mild ID (American Psychiatric Association, 2000).
However, most studies often use a simpler classification where
the patients are categorized as mild ID when the IQ lies between
50 and 70 or severe ID when the IQ is below 50. Under this
simpler classification, only 20% of mild ID cases have any con-
clusive genetic causes whereas other cases are largely attributed
by environmental factors such as malnutrition during pregnancy,
infections, fetal alcohol syndrome, premature birth or exposure
to neurotoxic compounds (Van Bokhoven, 2011). By contrast,
about 50–65% of severe ID cases are commonly associated with
genetic disorders resulted from chromosomal abnormalities, dys-
regulation of genetic imprinting, or monogenic disorders (Van
Bokhoven, 2011).
The most prevalent genetic abnormalities associated with ID is
chromosomal aberrations, such as trisomy 21 in Down syndrome
(DS), trisomy 18 in Edward syndrome, the presence of extra chro-
mosome X in males with Klinefelter syndrome or monosomy
X in females with Turner syndrome, and chromosomal dele-
tions at 22q11 in DiGeorge syndrome. Angelman syndrome and
Prader–Willi syndrome are examples of genetic disorders caused
by dysregulation of genetic imprinting, with ID as one of the com-
mon clinical features. On the other hand, monogenic disorder for
ID is rare and commonly manifested as non-syndromic ID. It is
also commonly known as X-linked ID (XLID) because most of
the associated genes are located on the X chromosome. Coffin–
Lowry syndrome is an example of XLID that arises as a result of
X-linked dominant inheritance of mutated RPS6KA3 (ribosomal
protein S6 kinase, 90 kDa polypeptide 3) on the X chromosome
(Kleefstra et al., 2005).
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Understanding the affected molecular pathways and cellu-
lar processes due to genetic abnormalities will help to unravel
mechanisms underlying ID. However, the association between
the genetic abnormalities and ID has remained unclear. In the
past two decades, the discoveries of microRNAs (miRNAs), a
class of small non-coding RNA about 18–24 nucleotides (nt),
had brought new perspective to the studies of ID (Bartel, 2004).
The discovery of a small RNA transcript lin-4 in 1993 through a
genetic screening in the nematodes Caenorhabditis elegans and its
roles in regulation of lin-14 translation via antisense RNA–RNA
interaction have brought forth the beginning of the era of miR-
NAs and non-coding RNAs (Lee et al., 1993; Wightman et al.,
1993). The era of miRNAs truly took off after the second miRNA,
let-7, was discovered in 2000 in C. elegans. Let-7 functions sim-
ilarly as lin-4 and was found to be conserved throughout meta-
zoans (Reinhart et al., 2000). This finding sparks off a large scale
searches for other miRNAs and their roles in regulating cellular
and molecular processes (Lagos-Quintana et al., 2001; Lau et al.,
2001; Lee and Ambros, 2001).
Since the discovery of lin-4 and let-7, a total of 21,264 miRNA
entries were indexed in miRBase (www.mirbase.org; miRBase
v19 accessed on 8/11/2012) for various organisms ranging from
mammals (e.g., human, chimpanzee, mouse, cattle) to zebrafish,
plants, arthropods, and viruses. Figure 1A shows the number of
miRNAs indexed in miRBase v19 for selected organisms and the
human genome harbors the greatest number of miRNAs that are
FIGURE 1 | (A) Total number of precursor and mature miRNAs from
various species of organisms indexed by miRBase (www.miRBase.org;
miRBase v19 accessed on 8/11/2012). (B) The Venn diagram shows the
total number of neuroscience- and miRNA-related literature indexed in
PubMed. Neuroscience-related literature were searched based on the
following terms/functions used in the title/abstract of the literature; (1)
neuroscience or (2) brain or (3) neuron or (4) neuron or (5) glia or
(6) nervous system. MiRNA-related literature were searched based on (1)
miRNA or (2) microRNA or (3) lin-4 or (4) let-7 terms/functions. Total
numbers of overlapping literature between the two groups of
literature were searched based on the combined terms/functions:
neuroscience-related search terms AND miRNA-related search terms. The
graph shows the number of neuroscience-miRNA-related literature
indexed in PubMed since 2000.
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reported to date (approximately 10% of all known miRNAs). In
addition, the miRNA genes are not randomly distributed across
the mammalian genome because some chromosomes in human
(e.g., HSA19) and mouse (e.g., MMU2 and MMU12) genomes
have exceptionally high density of miRNA genes as compared to
the global average (Figure 2). The non-random genomic distri-
bution of miRNA genes across the human genome or within a
chromosome has been associated with dysregulated expression
levels of miRNAs that may lead to diseases (Calin et al., 2004;
Albano et al., 2010). Besides, changes of the copy number for
miRNA genes due to aneuploidy may serve as one of the many
causes of ID. Somatic mosaicisms in neurons due to aneuploidy
have been identified in the mammalian brain and constitute
only a small proportion of all neurons. These aneuploid neu-
rons are resulted from errors in chromosomal segregation during
normal progenitor cells proliferation and are integrated within
circuitries of the normal brain (Rehen et al., 2001, 2005; Yang
et al., 2003; Kingsbury et al., 2005). Taken together, the effect
of non-random genomic distribution and imbalance dosage of
miRNA genes in ID developmentmay serve as an important piece
of missing puzzle in understanding various genetic syndromes
of ID.
To date, a great number of miRNAs have been shown to
be associated with the development and function of nervous
system (Christensen and Schratt, 2009; Fiore et al., 2011; Im
and Kenny, 2012; McNeill and Van Vactor, 2012). The role of
miRNAs in molecular regulation of gene expression in neurons
(Siegel et al., 2011), learning and memory (Konopka et al., 2011),
and the development of neurological disorders (Forero et al.,
2010; Satoh, 2010) has been extensively reviewed. Since 2000, the
total number of indexed literature in PubMed that are related
to the field of neuroscience and miRNA has increased tremen-
dously (Figure 1B). However, the role of miRNAs in ID has not
gained much attention to date, thus in this review, we will pro-
vide a brief overview on miRNA biogenesis and function and
highlight the involvement of miRNAs in molecular mechanisms
related to ID with special focus on DS, XLID, and Fragile X
syndrome (FXS).
MiRNA BIOGENESIS AND FUNCTION
MiRNAs are transcribed from their genes by either RNA poly-
merase II or III into a long primary transcript (pri-miRNAs)
that folded itself into a hairpin structure (Figure 3) (Lee et al.,
2004; Borchert et al., 2006). These miRNAs genes are located in
both coding and non-coding genes across different regions in the
genome. Frequently, miRNAs are transcribed from the introns of
protein coding genes (Rodriguez et al., 2004; Saini et al., 2007).
In addition, miRNAs are also transcribed from the non-coding
FIGURE 2 | The normalized number of precursor and mature miRNAs
per 10Mbs indexed by miRBase for (A) human and (B) mouse
(www.miRBase.org; miRBase v19 accessed on 8/11/2012). Red-dotted
horizontal lines denote the average mature miRNAs per 10Mbs across the
genome. Gray-dotted horizontal lines denote the number of standard
deviation (SD) from the global average value.
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FIGURE 3 | MiRNA biogenesis and mode of action (DGCR8, DiGeorge Critical Region 8; RISC, RNA-induced silencing complex; RNA Pol II, RNA
polymerase II; TRBP, Tar-RNA binding protein; Xpo5, Exportin-5).
region as part of long non-coding RNAs and are often arranged
in clusters in the genome, leading to the formation of several
miRNAs from the same pri-miRNA transcript (Rodriguez et al.,
2004).
Following the transcription into pri-miRNA, the primary
transcripts are then further processed in two stages by two dif-
ferent enzymes from the RNase III family; Drosha in the nucleus
and Dicer in the cytoplasm. Drosha, in concert with DiGeorge
Critical Region 8 (DGCR8) protein, facilitate the nuclear cleavage
of pri-miRNAs into a ∼60–90 nt stem loop intermediate resem-
bles hairpin and termed as precursormiRNAs (pre-miRNAs) (Lee
et al., 2003). The cleavage happened at the 5′ and 3′ arms of
the pri-miRNAs hairpin by the action of two RNase domains on
Drosha (Han et al., 2004). During the cleavage, DGCR8 is needed
to stabilize the Drosha at its middle domain as well as to deter-
mine the exact cleavage site in the pri-miRNA. Subsequently, the
resulted pre-miRNA hairpin is exported into the cytoplasm with
the aid from a nuclear transport receptor, Exportin-5 (Xpo5) (Yi
et al., 2003; Lund et al., 2004).
In the cytoplasm, pre-miRNAs are further processed into RNA
duplexes of miRNA:miRNA∗ by Dicer with the help of its cofac-
tor, Tar-RNA binding protein (TRBP) (Chendrimada et al., 2005;
Haase et al., 2005). There is an additional cleavage step for miR-
NAs that have high degree of complementarity along the hairpin
stem by the action of Argonaute-2 (Ago2) which generates a
nick in the middle of the prospective passenger strand (comple-
mentary strand to the mature miRNA that usually exists in low
level), resulting in Ago2-cleaved pre-miRNA (ac-pre-miRNA)
(Diederichs and Haber, 2007). The loop on both pre-miRNA and
ac-pre-miRNA are then cleaved by Dicer to generate a miRNA
duplex of about 22 nt in length.
The miRNA duplex generated from Dicer-mediated cleav-
age need to be separated into a functional guide strand that is
complementary to the target and the passenger strand is usu-
ally degraded. The generation of the single stranded guide strand
as the mature miRNA requires the unwinding activity of heli-
case. However, a universal helicase responsible for this has not
been identified to date. The single stranded guide miRNA will be
incorporated into a ribonucleoprotein effector complex, termed
as RNA-induced silencing complex (RISC). Then, the miRNA
directs the RISC to the target mRNA by binding to the 3′ UTR
of the targeted mRNA. Nucleotides at positions 2–8 at 5′ region
of the miRNA is known as the seed sequence and is involved
in recognizing the target mRNA (Bartel, 2004). The choice of
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mRNA posttranscriptional regulation mechanisms depends on
the complementarity of the seed sequence as well as supplemen-
tary binding of 3′ region of the miRNA with the 3′ UTR of the
target mRNA. If the miRNA has perfect or sufficient comple-
mentarity to the mRNA, RISC will cleave off the target mRNA
leading to mRNA degradation. Translational repression will hap-
pen instead if the miRNA:mRNA binding is imperfect (Bartel,
2004) leading to increased rate of degradation due to deadeny-
lation of the mRNA (Eulalio et al., 2009). The deadenylation
of mRNAs by miRNAs initiated the hypothesis that complete
deadenylation leads to disruption of the interaction of poly(A)-
binding protein and the cap, thus reducing the translation of
the mRNAs. However, a recent publication demonstrated that
in the case of miR-430, the translational repression occurred
independent of the deadenylation (Bazzini et al., 2012). The
author suggested that the miRNAs with partial complementar-
ity to its target may trigger both translational repression and
deadenylation to ensure maximum target mRNA repression and
degradation.
MiRNA AND DOWN SYNDROME
DS is a genetic disorder of trisomy human chromosome 21
(HSA21) with live birth prevalence of 11.2 per 10,000 births
(Loane et al., 2012). All DS patients exhibit ID. They also develop
other clinical features such as typical craniofacial appearance
(e.g., brachycephaly, epicanthic fold and protruding tongue),
hypotonia, congenital heart defects, early onset of Alzheimer’s
disease (AD), dementia as well as cognitive impairment (Van
Cleve and Cohen, 2006; Van Cleve et al., 2006). Mild to severe
intellectual disabilities were observed inDS patients with reported
average value of 50 in IQ and learning disabilities involving
both long-term and short-term memory formation (Brown et al.,
2003; Vicari et al., 2005). The extra HSA21 caused various
neuroanatomical abnormalities in DS patients such as reduc-
tion in brain size, brain weight as well as neuronal density,
neuronal distribution, and dendritic abnormalities at cellular
level (Wisniewski, 1990; Takashima et al., 1994; Kaufmann and
Moser, 2000). There have been many hypotheses proposed to
correlate the extra HSA21 to DS phenotypes such as gene
dosage imbalance hypothesis, amplified developmental instability
hypothesis, and critical region hypothesis (Delabar et al., 1993;
Pritchard and Kola, 1999; Antonarakis et al., 2004). There is
growing interest in epigenetic modifications, allelic differences,
gene dosage compensation and also additive, subtractive, and
epistatic patterns of genetic contribution to DS phenotypes (Dey,
2011).
Latest statistic from miRBase (www.mirbase.org; miRBase v19
accessed on 21/12/2012) indicates that there are 19 precursors and
26 mature miRNAs located on HSA21 but only five of them have
been implicated in DS so far such as miR-155, miR-802, miR-
125b-2, let-7c, and miR-99a (as summarized in Table 1) (Kuhn
et al., 2008). These miRNAs are overexpressed in DS fetal hip-
pocampus and heart samples and are exclusively expressed in
neurons but not in microglial cells or astrocytes. Interestingly,
neurons expressing these miRNAs were found increased by 10–15
fold in DS fetal hippocampus samples as compared to age- and
sex-matched controls (Kuhn et al., 2008).
Trisomic overexpression of HSA21-derived miRNA is believed
to contribute, in part, to the defective neurodevelopment in DS
individuals. Overexpression of miR-155 and miR-802 (Table 1)
in Ts65Dn (a genetic mouse model of DS) hippocampus may
contribute to impaired hippocampal synaptic plasticity and neu-
rogenesis (Keck-Wherley et al., 2011). BothmiR-155 andmiR-802
target the methyl CpG binding protein 2 (MeCP2) (Kuhn et al.,
2010), which is associated with deleterious effects on develop-
ment as seen in Rett Syndrome (Cohen et al., 2003). Silencing
of these two miRNAs in Ts65Dn is able to restore the MeCP2
expression and its target genes (Kuhn et al., 2010). Overexpression
of miR-155 and miR-802 and low expression of MeCP2 were
observed in induced pluripotent stem cells (iPSC) from human
DS amniotic fluids cells (Lu et al., 2012). Interestingly, a study
in mouse model of Rett Syndrome showed thatMeCP2 repressed
miR-199b expression in the mouse brain (Urdinguio et al., 2010)
and miR-199b has been shown to suppress sirtuin 1 (SIRT1)
(Saunders et al., 2010), which is involved in dendritic devel-
opment (Codocedo et al., 2012). Reduction of SIRT1 promotes
neurogenic potential of adult subventricular zone and hippocam-
pal neural precursors (Saharan et al., 2013). As aforementioned,
overexpression of miR-155 and miR-802 have been found to
repress MeCP2 expression (Kuhn et al., 2010), therefore these
HSA21-miRNAs in DS brain are expected to repress MeCP2 and
subsequently relieve the suppression on miR-199b and decreased
SIRT1 expression. This interconnected cascade of regulations
suggests a series of complex events that may be disrupted in
DS brain development. Selective inactivation on these HSA21-
derived miRNAs can be employed as a novel therapeutic tool in
the future.
DS is also characterized by brain deficits and systemic immune
pathology such as activated microglia and increased inflamma-
tory signaling. Overexpression of miR-155 and repression of
complement factor H (CFH), an essential repressor of the innate
immune response were observed in brains and peripheral tis-
sues of DS individuals (Li et al., 2012). Interestingly, miR-155
was overexpressed in AD and was found to regulate CFH expres-
sion (Lukiw and Alexandrov, 2012). It was predicted to interact
with presynaptic mRNAs such as phosphatidylinositol-binding
clathrin assembly protein (PICALM) (Paschou et al., 2012), which
has been implicated in AD (Melville et al., 2012). As DS patients
are prone to develop early onset AD, association betweenmiR-155
and brain pathology should be further investigated to unravel its
role in regulating innate immune and inflammatory responses.
There have been efforts made to unravel the role of miR-125b
(summarized in Table 1) in the neuropathology of DS subjects.
MiR-125b was significantly upregulated in interleukin-6-stressed
normal human astrocytes (Pogue et al., 2010). Anti-miR-125b
treatment attenuated astrogliosis and increases cyclin-dependent
kinase inhibitor 2A (CDKN2A), a negative regulator of cell
growth. Astrogliosis in DS brains could be attributed to the
glial proliferative effect of miR-125b via suppression of CDKN2A
(Pogue et al., 2010). In addition, miR-125b also targeted glu-
tamate receptor, ionotropic, N-methyl d-aspartate subunit 2A
(NR2A), Ephrin type A receptor 4 (EPHA4), andNestin (Edbauer
et al., 2010; Cui et al., 2012). Mir-125b is crucial for spine mor-
phology development and neuronal survival (Schaefer et al.,
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MeCP2 (Keck-Wherley et al., 2011)
CFH (Li et al., 2012)
PICALM (Paschou et al., 2012)
DS individuals Overexpressed in fetal hippocampus and heart samples (Kuhn
et al., 2008).
Overexpressed in prefrontal cortex samples at all ages studied
(from fetus to adulthood) (Kuhn et al., 2010).
Overexpressed in the adult temporal lobe, the spleen, and the
liver (Li et al., 2012).
Ts65Dn mouse model for DS Overexpressed in the adult hippocampus (Kuhn et al., 2010).
Overexpressed in adult hippocampus and blood samples
(Keck-Wherley et al., 2011).
Anti-miR treatment restored MeCP2 in adult hippocampus
(Kuhn et al., 2010).
iPSCs generated from human DS
amniotic fluid cells
Overexpressed in iPSCs (Lu et al., 2012).
TNFα-stressed human neuronal-glial
cells
Anti-miR treatment restored CFH level (Li et al., 2012).
Superior temporal neocortex of AD Overexpressed in neocortical samples (Lukiw and Alexandrov,
2012).
miR-802
MeCP2 (Keck-Wherley et al., 2011)
DS individuals Overexpressed in fetal hippocampus and heart samples (Kuhn
et al., 2008).
Overexpressed in prefrontal cortex samples at all ages studied
(from fetus to adulthood) (Kuhn et al., 2010).
Ts65Dn mouse model for DS Overexpressed in the adult hippocampus (Kuhn et al., 2010).
Overexpressed in adult hippocampus and blood samples
(Keck-Wherley et al., 2011).
Anti-miR treatment restored MeCP2 in adult hippocampus
(Kuhn et al., 2010).
iPSCs generated from human DS
amniotic fluid cells
Overexpressed in iPSCs (Lu et al., 2012).
miR-199b
Dyrk1a (Da Costa Martins et al., 2010)
SIRT1 (Saunders et al., 2010)
Heart failure patients Overexpressed in biopsies of cardiac tissues (Da Costa Martins
et al., 2010).
MHC-CnA mouse Overexpressed in heart samples (Da Costa Martins et al., 2010).
Anti-miR treatment restored Dyrk1a level in the heart (Da Costa
Martins et al., 2010).
Mouse embryonic stem cells Overexpressed miR-199b reduced SIRT1 protein level
(Saunders et al., 2010).
miR-125b
CDKN2A (Pogue et al., 2010)
NR2A and EphA4 (Edbauer et al., 2010)
Nestin (Cui et al., 2012)
IL-6-stressed NHA Overexpressed in IL-6-stressed NHA (Pogue et al., 2010).
Anti-miR treatment restored CDKN2A level (Pogue et al., 2010).
Hippocampus of newborn
Sprague-Dawley rat pups
Overexpressed miR-125b reduced Nestin expression and inhibit
neural stem/progenitor cells proliferation (Cui et al., 2012).
E19 rat hippocampal neurons in
culture
FMRP was partially depending on miR-125b in suppressing
NR2A (Edbauer et al., 2010).
Overexpressed miR-125b led to longer and thinner dendritic
protrusions with reduced synaptic strength (Edbauer et al.,
2010).
(Continued)
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miR-125b-2 DS individuals Overexpressed in fetal hippocampus and heart samples (Kuhn
et al., 2008).
Overexpressed in prefrontal cortex samples at all ages studied
(from fetus to adulthood) (Kuhn et al., 2010).
miR-99a
TGF-β pathway (Turcatel et al., 2012)
let-7c
TLP7 (Lehmann et al., 2012)
DS individuals Overexpressed in fetal hippocampus and heart samples (Kuhn
et al., 2008).
Overexpressed in prefrontal cortex samples at all ages studied
(from fetus to adulthood) (Kuhn et al., 2010).
iPSCs generated from human DS
amniotic fluid cells
Overexpressed in iPSCs (Lu et al., 2012).
miR-214
CTTNBP2 and ANK2 (Paschou et al., 2012)
Ncx1 (Aurora et al., 2012)
Ts65Dn mouse model for DS Overexpressed in adult hippocampus samples (Keck-Wherley
et al., 2011).
miR-214 KO mouse Increased NCX1 protein in heart samples (Aurora et al., 2012).
miR-223
GluR2 and NR2B (Harraz et al., 2012)
Ts65Dn mouse model for DS Overexpressed in adult hippocampus and blood samples
(Keck-Wherley et al., 2011).
XLID individuals Mutation found in pre-miRNA sequence (Chen et al., 2007).
P15–P20 miR-223 KO mouse
hippocampal neurons
Increased GluR2 and NR2B protein levels, and promoted
NMDA-induced calcium influx (Harraz et al., 2012).
P15–P20 miR-223 WT mouse
hippocampal neurons
Overexpressed miR-223 caused NMDA-induced calcium influx
inhibition (Harraz et al., 2012).
miR-222 XLID individuals Mutation found in pre-miRNA sequence (Chen et al., 2007).
Small RNA libraries from 26 different
organ systems and cell types of
human and rodents (Landgraf et al.,
2007)
X-chromosomal miRNAs expressed in the midbrain, the
hippocampus, and the cortex (Mendoza et al., 2010).
miR-363
FXR1P (Cheever et al., 2010)
XLID individuals Mutation found in pre-miRNA sequence (Chen et al., 2007).
Small RNA libraries from 26 different
organ systems and cell types of
human and rodents (Landgraf et al.,
2007)
X-chromosomal miRNAs expressed in the midbrain (Mendoza
et al., 2010).
HEK-293T cells Downregulated the expression of FXR1P (Cheever et al., 2010).
miR-221 Small RNA libraries from 26 different
organ systems and cell types of
human and rodents (Landgraf et al.,
2007)
X-chromosomal miRNAs expressed in the hippocampus and the
cortex (Mendoza et al., 2010).
let-7f-2 X-chromosomal miRNAs expressed in the midbrain, the
hippocampus, and the cortex (Mendoza et al., 2010).
miR-19b-2 X-chromosomal miRNAs expressed in the midbrain (Mendoza
et al., 2010).
miR-92a-2, miR-374b X-chromosomal miRNAs expressed in the midbrain and the
hippocampus (Mendoza et al., 2010).
(Continued)
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miR-98, miR-374a X-chromosomal miRNAs expressed in the midbrain and the
cortex (Mendoza et al., 2010).
miR-105-2 X-chromosomal miRNAs expressed in the cortex (Mendoza
et al., 2010).
miR-132 E19 rat hippocampal neurons in
culture
Overexpressed miR-132 led to stubby and mushroom dendritic
spines with an increase in average protrusion width as well as
the synaptic strength (Edbauer et al., 2010).
miR-92b, miR-367
FXR1P (Cheever et al., 2010)
HEK-293T cells Downregulated the expression of FXR1P (Cheever et al., 2010).
miR-9, miR-124 fxr1 KO mice Both pre-miR-9 and pre-miR-124 required FXR1P to efficiently
process them into mature miRNAs in vitro (Xu et al., 2011).
miR-19b, miR-302b*, miR-323-3p
FMR1 (Yi et al., 2010)
HEK-293 cells Potential repressors of the FMR1 gene (Yi et al., 2010).
15-LOX, 15-lipoxygenase; AD, Alzheimer’s disease; ANK2, ankyrin 2; CDKN2A, cyclin-dependent kinase inhibitor 2A; CTTNBP2, cortactin-binding protein 2; CFH,
complement factor H; DS, Down syndrome; Dyrk1a, dual specificity tyrosine-phosphorylation-regulated kinase 1A; E19, embryonic day 19; EPHA4, Ephrin type A
receptor 4; FMR1, fragile X mental retardation 1; fxr1, Farnesoid X receptor 1; FXR1P, fragile X related protein 1; GluR2, glutamate receptor, ionotropic, AMPA2
(alpha 2); IL-6, interleukin-6; iPSC, induced pluripotent stem cell; KO, knockout; MeCP2, methyl CpG binding protein 2; MHC-CnA, myosin heavy chain-calcineurin;
Ncx1, sodium-calcium exchanger 1; NHA, normal human astrocytes; NMDA, N-methyl D-aspartate; NR2A, NMDA subunit 2A; NR2B, NMDA subunit 2B; P, postnatal;
PICALM, phosphatidylinositol-binding clathrin assembly protein; SIRT1, sirtuin1; TGF-β, transforming growth factor-β; TLP7, toll-like receptor 7; TNF, tumor necrosis
factor; UTR, untranslated region; WT, wildtype; XLID, X-linked intellectual disability; *denotes the passenger strand of a miRNA.
2007). It stimulates neurite outgrowth and dendritic branching
(Le et al., 2009) which produced longer and thinner dendritic
spine with reduced spine width by targetingNR2A (Edbauer et al.,
2010). Suppression of NR2A and EphA4 have been implicated in
long-term potentiation (LTP) and/or long-term depression (LTD)
processes (Zhao and Constantine-Paton, 2007; Filosa et al., 2009;
Xu et al., 2009). In a Luciferase reporter assay, miR-125b was
shown to target 3′UTR of Nestin and reduced both Nestin mRNA
and protein levels. When overexpressed, miR-125b inhibited neu-
ral stem/progenitor cells proliferation via suppression of Nestin
(Cui et al., 2012). Taken together, it is evident that the overex-
pression ofmiR-125b may lead to significant changes in neuronal
development. The role of miR-125b in targeting various tran-
scripts leading to impaired synaptogenesis and LTP in DS subjects
should be investigated.
Mir-99a regulates transforming growth factor-β (TGF-β)
pathway (Turcatel et al., 2012) which directly involved in retro-
grade synaptic signaling (Sanyal et al., 2004) and regulates Wnt
signaling in stem cell differentiation (Cai et al., 2013). On the
other hand, let-7c is highly expressed in the hippocampal region
of adult mice (Bak et al., 2008). It has been shown to cause neu-
ronal loss in a dose- and time-dependent manner by acting on
toll-like receptor 7 (TLR7) (Lehmann et al., 2012). Role of mir-
99a and let-7c in regulating neuronal function in DS individuals
warrant further investigations.
Children with DS often experience auditory deficits
(Cunningham and McArthur, 2006), language difficulties
which include reading impairment (Lemons and Fuchs, 2010;
Nash and Heath, 2011) and limited verbal short-term memory
capacity (Jarrold et al., 2002; Brock and Jarrold, 2005). These DS-
associated impairments will generally lead to learning disabilities
in DS children. MiR-125b-2, let-7c, and miR-99a are the three
HSA21-derived miRNAs which orthologs were found expressed
in the mouse inner ear (Weston et al., 2006). An increased in
the size of the large conductance calcium activated potassium
(BK) current (which is known to determine electrical tuning)
was observed in Tc1 (another mouse model for DS that carries
a significant portion of HSA21) inner hair cells as compared to
control (Kuhn et al., 2012). Thus, the roles of miR-125b-2, let-7c,
and miR-99a should be validated in human samples to better
understand their roles in regulating auditory development or
function in DS individuals.
Other non HSA21-derived miRNAs such as miR-214 and
miR-223 were found overexpressed in the adult Ts65Dn hip-
pocampus (Keck-Wherley et al., 2011) but their expression pro-
files have not been extensively characterized in DS individuals.
Mir-214 was predicted to regulate cortactin-binding protein 2
(CTTNBP2) and ankyrin 2 (ANK2) that code for synaptic pro-
tein (Paschou et al., 2012). It also repressed sodium-calcium
exchanger 1 (Ncx1) (Aurora et al., 2012), which is crucial for
spine-dendrites compartmentalization (Lörincz et al., 2007) and
presynaptic calcium recovery mechanism in cerebellar parallel
fiber (Roome et al., 2013). MiR-223 has been reported to func-
tion as a regulator on glutamate receptor subunits NR2B and
GluR2 and its overexpression led to NMDA-induced calcium
influx inhibition on hippocampal neurons (Harraz et al., 2012).
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Downstream gene targets of both miR-214 and miR-223 have
important roles in regulating neuronal development and func-
tion, however, the direct association between these miRNAs and
their targets with neuronal dysfunction in DS are yet to be
determined.
MiRNAs derived from other chromosomes but targeted
genes located on HSA21 may contribute to the phenotypes
of DS. For instance, both mouse chromosome 9-derived miR-
199b and human chromosome 2-derived miR-1246 are known
to downregulate DS associated dual-specificity tyrosine-(Y)-
phosphorylation regulated kinase 1A gene (Dyrk1a—encoded
in MMU16; DYRK1A—encoded in HSA21) and subsequently
induce apoptosis through nuclear factor of activated T-cells
(NFAT) pathway (Da Costa Martins et al., 2010). Dyrk1a with
dysregulated NFAT signaling has been reported in DS individuals
(Arron et al., 2006). NFAT signaling pathway has been impli-
cated in AD (Abdul et al., 2009; Hudry et al., 2012). Based on the
AD model, further investigation of both miR-199b:Dyrk1a and
miR-1246:DYRK1A interactions may provide an insight on mech-
anisms mediated by these miRNAs in ID progression among DS
individuals.
In brief, HSA21-harbored miRNAs are directly involved in
neuronal differentiation, neuronal development, synaptic plastic-
ity and more. Their roles in DS may shed light in understanding
the underlying mechanisms in the development of ID More
excitingly, miRNA-based therapies have been shown to restore
expression of targeted genes as well as their downstream activities.
Restoration of defective neurogenesis, gliogenesis and cell cycles
events have not been fully explored and these warrant further
investigation to better understand ID development inDS patients.
MiRNA AND X-LINKED INTELLECTUAL DISABILITIES
X chromosome plays a major role in the development of sex-
ual characteristics and it harbors many genes that are involved
in cognitive functions. XLID broadly refer to different forms of
ID that are inherited as X-linked traits. First reported in 1938,
Lionel Penrose observed higher number of males suffered from
ID than female from a survey and classification of those in institu-
tional care and their relatives (Penrose, 1938). He also found that
the ratio between male to female ID patients was 1.25:1, which
was eventually confirmed by many other studies in USA, Canada,
Australia as well as Europe with all the studies came into agree-
ment that about 30% excess of males as compared to female were
affected by ID (Raymond, 2006). From various family studies, it
was then discovered that many of the IDwas inherited as X-linked
trait. Hence, XLID typically affects the male population with mild
to severe ID. Females are less likely to be affected by XLID. If they
are affected, they developed milder ID symptoms than the male.
This is due to X chromosome inactivation where one of the two
X chromosomes in female is inactivated randomly early in devel-
opment. The X-inactivation is a dosage correction mechanism in
female to prevent the double dosage effect of the genes on both
X chromosomes. For female with XLID, the mechanism could
reduce the effect of mutated or deleted genes by inactivating the
affected X chromosome.
XLID is manifested in more than 150 syndromes, includ-
ing FXS, Klinefelter syndrome, Rett syndrome, Coffin–Lowry
syndrome, and X-linked alpha thalassemia. To date, 102 X-linked
genes have been associated to 82 syndromes with mutations in
these genes described as the causes (Stevenson et al., 2012).
However, the identification of genes that are responsible for other
XLID syndromes had been unsuccessful due to the rarity of the
syndromes or the difficulty in identifying the genes involved. This
has impeded the progression in XLID related research.
In 2007, a large-scale mutation screening of miRNAs in
patients with ID was reported (Chen et al., 2007). A cohort
of 464 patients with XLID has been screened for mutations
in 13 known, brain expressed X-chromosomal miRNAs. Four
nucleotide changes in three different pre-miRNAs (miR-222,miR-
223, and miR-363; Table 1) have been observed in the study
though the changes appeared to be functionally neutral and did
not affect the function of the respective miRNAs. The authors
suggested that the functionally neutral mutations on the miRNAs
indicate a strong selection on the pre-miRNA and thus reflecting
on the general importance of miRNA system.
Mendoza and colleagues are interested in the potential roles
of brain expressed X-chromosomal miRNAs especially in the
context of human intelligence and they attempted such inves-
tigation by using informatics tools (Mendoza et al., 2010). By
mining the Mammalian miRNA Expression Atlas based on Small
RNA Library Sequencing (Landgraf et al., 2007), 77 human
X-chromosomal miRNAs was identified and ten were further
selected for target genes prediction as well as gene ontologies
(GO) analysis by virtue of their differential levels in the cortex,
hippocampus and midbrain. The ten miRNAs selected were let-
7f-2, miR-19b-2, miR-92a-2, miR-98, miR-105-2, miR-221, miR-
222, miR-363, miR-374a, and miR-374b (Table 1). Out of the 10
miRNAs, only let-7f-2 andmiR-222 were expressed in all the three
brain regions studied indicating that they may play an impor-
tant role in regulating brain function. Target genes for all the 10
selected miRNAs were predicted using in silico tools (MiRanda,
TargetScan, and MirTarget2) and results from all analyses were
pooled for GO annotation enrichment analysis. The enrichment
analysis showed that many biological processes were associated
with brain development including the development of the fore-
brain, midbrain as well as hippocampus. These results show that
X chromosome is a potential repository for genes highly expressed
in the brain and may have roles in regulating the development or
function of nervous system.
MiRNA AND FRAGILE X SYNDROME
FXS, also known as Martin Bell syndrome, is one of the most
common forms of XLID with an estimated prevalence of 1 in
4000 males and 1 in 8000 females (Warren and Sherman, 2001).
The syndrome is transmitted as an X-linked dominant trait and
individuals with the syndrome are presented with mild to severe
ID (IQs in the range of 20–70), mild abnormal facial features
(mainly in males), as well as macroorchidism in postpubescent
males (Warren and Nelson, 1994). The loss-of-function muta-
tion on fragile mental retardation 1 (FMR1) gene, due to the
trinucleotide expansion of CGG repeat in 5′ untranslated region
(UTR), has been identified as the cause for FXS. The large trin-
ucleotide expansion has been associated with hypermethylation
of both the CGG repeat and upstream CpG islands, resulting
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in transcriptional silencing of FMR1, which leads to the loss of
its product, fragile X mental retardation protein (FMRP) (Jin
et al., 2004a). As a translation repressor, miRNAs may play a role
in downregulating the production of FMRP. For example, miR-
19b, miR-302b∗, and miR-323-3p (Table 1) were shown to target
3′ UTR of FMR1 in a luciferase reporter gene assay (Yi et al.,
2010). This suggests that the expression of FMRP is susceptible
to miRNA regulation by targeting FMR1 transcripts. Such inci-
dent, however, have not been demonstrated or validated in FXS
subjects to date.
FMRP is an RNA-binding protein which plays a role in mRNA
transport and translational regulation especially in the synap-
tic region of neurons. Loss of functional FMRP impairs normal
synaptic plasticity, which is believed to be the molecular basis
for ID in FXS patients (Bassell and Warren, 2008). Comparing
miRNAs targets predicted by miRanda with datasets of FMRP-
bound mRNAs, 74% of the mRNAs were found to be matching
with miRNAs target genes (John et al., 2004). This suggests that
some of the translation may be regulated through actions of
both FMRP and miRNAs, indicating a close association between
both. Indeed, it was shown that FMRP interacts with miRNAs as
well as its machinery including Dicer and mammalian ortholog
of Argonaute 1 (AGO1) in mammalian cell cultures (Jin et al.,
2004b). FMRP also facilitate the assembly of miRNAs on spe-
cific target mRNAs by acting as a miRNA acceptor protein for
Dicer (Plante et al., 2006). RNAs targeted by FMRP were involved
in synaptic signaling pathways such as synaptic LTP, glutamate
receptor signaling, neuropathic pain signaling, GABA receptor
signaling, synaptic LTD and CREB signaling in neurons. FMRP
bound to its RNA targets mainly at the coding sequences and
stalled ribosomes (Darnell et al., 2011). Loss of FMRP func-
tion relieved the ribosomal stalling, thus suggesting that FMRP
may regulate translation at the level of elongation (Darnell et al.,
2011). Since FMRP could act as a miRNA acceptor from Dicer,
any defect in the function of FMRPwill not only cause abnormali-
ties in miRNA function but translational regulation of its targeted
mRNAs as well.
FMRP-associatedmiR-125b andmiR-132 have a crucial role in
regulating the structure and function of the synapses (Edbauer
et al., 2010). By overexpressing miR-125b in mouse hippocam-
pal neurons in culture, longer and thinner dendritic protrusions
with reduced synaptic strength were observed. Overexpression
of miR-132, however, resulted in stubby and mushroom spines
with an increased average protrusion width as well as the synap-
tic strength (Table 1). When FMRP was downregulated in vitro,
overexpression of both miR-125b and miR-132 did not cause any
phenotypic changes to the dendritic spinemorphology suggesting
both FMRP and its associated miRNAs were needed for trans-
lation regulation. Together with FMRP, miR-125b targeted and
suppressed NR2A, a subunit of NMDA (N-methyl-D-aspartate)
receptor (Edbauer et al., 2010), which has an important role
in LTP in cortex and amygdala, spike-timing-dependent plas-
ticity and ocular dominance plasticity (Li et al., 2002; Zhao
et al., 2005; Desai et al., 2006; Dölen et al., 2007; Meredith
et al., 2007). All these findings further solidified the poten-
tial role of miR-125b and FMRP in the synaptic plasticity and
function.
In addition to FMRP, another paralogs of FMRP known as
Fragile X-related protein 1 (FXR1P) was targeted and regulated
by miR-92b, miR-363, and miR-367 (Table 1). Overexpression
of miR-367 downregulated the expression of FXR1P in human
HEK-293 and HeLa cell lines (Cheever et al., 2010). Interestingly,
FXR1P was required to efficiently process pre-miR-9 and pre-
miR-124 into mature miRNAs in vitro. Loss of FXR1P led to
the downregulation of the brain specific miRNAs, that were cru-
cial to several aspects of neuronal development and function (Xu
et al., 2011). Mutations in either miRNA recognition sites for
miR-92b, miR-363, or miR-367 on FXR1P will result in increased
levels of FXR1P that leads to a lower level of miR-9 and miR-
124. Collectively these findings imply that FXR1P are far more
important than previously thought due to the facts that FXR1P
functions in processing pre-miRNAs and yet FXR1P itself are
regulated by miRNAs. This central role of FXR1P leads us to pos-
tulate that mutations on FXR1Pmay contribute to FXS essentially
due to disrupted miRNA-mediated translation regulation.
To date, there are no conclusive evidences that showed direct
link between miRNAs and FXS. However, the prospect of miR-
NAs in answering much of the question about FXS continues to
encourage researchers in pursuing miRNA as a potential break-
through to understand FXS. With its role as a regulator in the
expression of multitude of genes, miRNAs definitely will help in
filling much of the gaps in our understanding of XLID.
CONCLUSION
As much as we have progressed in the discovery of genes or mech-
anisms responsible for ID, many other syndromes where ID was
implicated remained elusive and under-investigated. These pose a
great challenge to researchers in their effort to better understand
the “universal” mechanism underlying the development and pro-
gression of broad-spectrum and heterogenous ID conditions. In
present day, miRNAs have the potential to bridge the missing
link between genetic abnormalities with ID especially in cases
where the causative genes could not be identified. In addition,
miRNAs’ unique characteristics of being able to target multiple
genes or that a single gene could be targeted by multiple miR-
NAs may explain the reason behind some severe ID conditions
where multiple genes are affected. The one-to-one, one-to-many,
and many-to-one mode of miRNA:mRNA interactions provide
us with a great versatility in designing experiments to study the
development and progression of ID as well as develop therapeu-
tic strategies aiming at pharmacologic inhibition of ID-associated
miRNAs. Besides drug based approach, various molecular thera-
pies based on small interfering RNA (siRNA) and locked nucleic
acid (LNA) have been tested and hold promises in treating genetic
disorders (Frieden and Ørum, 2008; Fluiter et al., 2009; Bernardo
et al., 2012; Chabot et al., 2012). In addition, the advent of
nanotechnology-based delivery system as well as advancement of
stem cell researches would make the goal of treating and improv-
ing the cognitive function of individuals with ID a reality in near
future.
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